These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 33875426)

  • 41. Increased risk of antipsychotic-related QT prolongation during nighttime: a 24-hour holter electrocardiogram recording study.
    Watanabe J; Suzuki Y; Fukui N; Ono S; Sugai T; Tsuneyama N; Someya T
    J Clin Psychopharmacol; 2012 Feb; 32(1):18-22. PubMed ID: 22198445
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of the potential for QTc prolongation in patients with solid tumors receiving nivolumab.
    Agrawal S; Waxman I; Lambert A; Roy A; Darbenzio R
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):635-41. PubMed ID: 26861469
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of enzastaurin and its metabolites on the QT interval in cancer patients.
    Welch PA; Ng WT; Darstein CL; Musib L; Lesimple T
    J Clin Pharmacol; 2016 Jan; 56(1):101-8. PubMed ID: 26096682
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen.
    Ndjeka N; Schnippel K; Master I; Meintjes G; Maartens G; Romero R; Padanilam X; Enwerem M; Chotoo S; Singh N; Hughes J; Variava E; Ferreira H; Te Riele J; Ismail N; Mohr E; Bantubani N; Conradie F
    Eur Respir J; 2018 Dec; 52(6):. PubMed ID: 30361246
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Population pharmacokinetic/pharmacodynamic modeling of delayed effect of escitalopram-induced QT prolongation.
    Kim Y; Kim A; Chung JY
    J Affect Disord; 2021 Apr; 285():120-126. PubMed ID: 33647579
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of 3 Single Doses of Trazodone on QTc Interval in Healthy Subjects.
    Tellone V; Rosignoli MT; Picollo R; Dragone P; Del Vecchio A; Comandini A; Radicioni M; Leuratti C; Calisti F
    J Clin Pharmacol; 2020 Nov; 60(11):1483-1495. PubMed ID: 32488885
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Absence of QTc Prolongation with Sodium N-(8-[2-Hydroxybenzoyl] Amino) Caprylate (SNAC), an Absorption Enhancer Co-Formulated with the GLP-1 Analogue Semaglutide for Oral Administration.
    Granhall C; Bækdal TA; Breitschaft A; Søndergaard FL; Anderson TW; Thomsen M
    Diabetes Ther; 2021 Sep; 12(9):2599-2610. PubMed ID: 34319564
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dose-related adverse events in South African patients prescribed clofazimine for drug-resistant tuberculosis.
    Misra N; Padayatchi N; Naidoo P
    S Afr Med J; 2019 Dec; 110(1):32-37. PubMed ID: 31865940
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies.
    Swaisland H; Plummer R; So K; Garnett S; Bannister W; Fabre MA; Dota C; Fielding A
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):775-84. PubMed ID: 27553432
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors.
    Olszanski AJ; Smith DC; Camacho LH; Thompson J; Ramalingam SS; Harvey RD; Campos L; Ferry D; Tang S; Gao L; Safran H
    Oncologist; 2016 Apr; 21(4):402-3. PubMed ID: 26984445
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Thorough QT study of the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor, on cardiac repolarization and conduction in healthy volunteers.
    He YL; Zhang Y; Serra D; Wang Y; Ligueros-Saylan M; Dole WP
    Curr Med Res Opin; 2011 Jul; 27(7):1453-63. PubMed ID: 21609207
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study.
    Matz J; Graff C; Vainio PJ; Kallio A; Højer AM; Struijk JJ; Kanters JK; Andersen MP; Toft E
    Clin Drug Investig; 2011 Nov; 31(11):799-811. PubMed ID: 21967071
    [TBL] [Abstract][Full Text] [Related]  

  • 53. PK/PD modeling of a clazosentan thorough QT study with hysteresis in concentration-QT and RR-QT.
    Henrich A; Juif PE; Dingemanse J; Krause A
    J Pharmacokinet Pharmacodyn; 2021 Apr; 48(2):213-224. PubMed ID: 33389549
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Which QT Correction Formulae to Use for QT Monitoring?
    Vandenberk B; Vandael E; Robyns T; Vandenberghe J; Garweg C; Foulon V; Ector J; Willems R
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27317349
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Increased incidence of QT interval prolongation in a population receiving lower doses of methadone maintenance therapy.
    Roy AK; McCarthy C; Kiernan G; McGorrian C; Keenan E; Mahon NG; Sweeney B
    Addiction; 2012 Jun; 107(6):1132-9. PubMed ID: 22168435
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identifying drug-induced repolarization abnormalities from distinct ECG patterns in congenital long QT syndrome: a study of sotalol effects on T-wave morphology.
    Graff C; Andersen MP; Xue JQ; Hardahl TB; Kanters JK; Toft E; Christiansen M; Jensen HK; Struijk JJ
    Drug Saf; 2009; 32(7):599-611. PubMed ID: 19530746
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical significance of QT-prolonging drug use in patients with MDR-TB or NTM disease.
    Yoon HY; Jo KW; Nam GB; Shim TS
    Int J Tuberc Lung Dis; 2017 Sep; 21(9):996-1001. PubMed ID: 28826448
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Meperidine-induced QTc-interval prolongation: prevalence, risk factors, and correlation to plasma drug and metabolite concentrations
.
    Keller GA; Villa Etchegoyen MC; Fernández N; Olivera NM; Quiroga PN; Diez RA; Di Girolamo G
    Int J Clin Pharmacol Ther; 2017 Mar; 55(3):275-285. PubMed ID: 27509828
    [TBL] [Abstract][Full Text] [Related]  

  • 59. PKPD and cardiac single cell modeling of a DDI study with a CYP3A4 substrate and itraconazole to quantify the effects on QT interval duration.
    Jaminion F; Bentley D; Wang K; Wandel C; Derks M; Diack C
    J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):447-459. PubMed ID: 32572738
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Thorough QT study with recommended and supratherapeutic doses of tolterodine.
    Malhotra BK; Glue P; Sweeney K; Anziano R; Mancuso J; Wicker P
    Clin Pharmacol Ther; 2007 Mar; 81(3):377-85. PubMed ID: 17339867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.